AVA-7100 / Avacta - LARVOL DELTA

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona (GlobeNewswire) - "With non-internalizing Affimer protein binding and extracellular warhead release by FAP, the AffDC optimizes the bystander effect, leading to effective killing of antigen-positive and antigen-negative tumor cells; AffDCs have an antigen-binding region of 14kDa (single-domain) or 28 kDa (two-domain) that is 10-20% of the size of an antibody, optimizing tumor penetration. AffDCs may be rapidly engineered for optimal biophysical and functional characteristics. The FAP AffDC molecules exhibit a broad range of FAP binding (including potency up to single-digit picomolar, pM) combined with highly tumor-specific warhead release by leveraging the preCISION linker to release warhead directly in the tumor microenvironment and target that delivery to tumors with low FAP expression."

Preclinical • Oncology • Solid Tumor

Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION Platform (GlobeNewswire) - "Avacta Group plc...today announces the addition of two novel preclinical oncology assets, AVA6103 and AVA7100, to its pipeline of pre|CISION-enabled drug conjugates...Further details of these programs will be released in conjunction with the Company’s two presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held in Barcelona from October 23-25, 2024. The platform and the pipeline will be presented at the investor and analyst R&D Spotlight Event: Focus on pre|CISION, in London on October 30, 2024."

Pipeline update • Oncology